Klivira
Request demo

Navigating Aetna Xultophy Prior Authorization Requirements

Successfully managing Aetna Xultophy prior authorization requests requires a precise understanding of payer-specific criteria and submission pathways. Klivira provides the operational clarity and automation to navigate these complexities.

For revenue cycle directors, prior authorization coordinators, and IT integration leads, the volume and specificity of prior authorization requirements for high-utilization medications like Xultophy present a significant operational challenge. This guide outlines the key considerations for submitting and managing Aetna Xultophy prior authorization requests, ensuring clinical and administrative alignment.

Xultophy Coverage and Aetna's Pharmacy Benefit

Xultophy, a combination of insulin degludec and liraglutide, is a high-volume prior authorization target primarily used in the management of type 2 diabetes. As a pre-filled injectable pen, Xultophy is typically managed under Aetna's pharmacy benefit, administered through CVS Caremark. Providers should anticipate formulary placement, step therapy protocols, and quantity limits as part of Aetna's utilization management criteria for this medication.

Aetna Prior Authorization Submission Channels for Xultophy

Aetna's submission channels for pharmacy-benefit prior authorizations vary. For outpatient retail pharmacy requests, Aetna leverages established ePA partners such as CoverMyMeds and Surescripts. For mail-order prescriptions or case-managed scenarios, submissions may route through CVS Caremark's direct provider portal. Understanding the correct channel is critical for timely processing and avoiding administrative delays.

Accessing Aetna's Clinical Criteria for Xultophy

Aetna's medical necessity criteria, including those for diabetes medications like Xultophy, are published as Clinical Policy Bulletins (CPBs) in the public Aetna CPB library. These CPBs are versioned and dated, serving as the canonical source for clinical requirements, step therapy protocols, and documentation standards. Providers must reference the specific CPB number and review date applicable to Xultophy to ensure compliance.

Common Denial Reasons and Appeal Pathways for Xultophy with Aetna

Prior authorization denials for Xultophy from Aetna often stem from insufficient documentation of medical necessity, failure to meet step therapy requirements, or off-label use without compendium support. When a denial occurs, Aetna's appeal pathway typically includes reconsideration, peer-to-peer review, and formal appeal. Expedited appeal processes are available for urgent care needs, with timely-filing windows varying by line of business and state regulations.

Turnaround Time Considerations for Aetna Xultophy PAs

Prior authorization turnaround times for Aetna are influenced by state-mandated minimums, payer-published service-level targets, and NCQA Utilization Management accreditation standards. For Aetna's Medicare Advantage and Medicaid managed-care lines (Aetna Better Health), CMS-0057-F mandates 72-hour decisions for standard PA requests and 24-hour for expedited, with phased compliance through 2027. Commercial plans are not directly impacted by CMS-0057-F, but state regulations and NCQA standards still apply.

Optimizing Aetna Xultophy Prior Authorization with Klivira

Klivira integrates with EMRs and payer portals, automating the submission and tracking of Aetna Xultophy prior authorization requests. By digitizing workflows and providing real-time status updates, Klivira helps reduce manual effort, minimize submission errors, and accelerate decision times. This operational efficiency allows your team to focus on patient care rather than administrative burdens.

Frequently asked questions

How do I submit a prior authorization for Xultophy to Aetna?

For Xultophy, which is typically a pharmacy benefit drug, prior authorizations are submitted electronically through ePA partners like CoverMyMeds or Surescripts for retail prescriptions. For mail-order or case-managed scenarios, submissions may route through the CVS Caremark provider portal.

Where can I find Aetna's clinical criteria for Xultophy?

Aetna publishes its clinical criteria, including those for diabetes medications like Xultophy, in its public Clinical Policy Bulletins (CPBs) library. These CPBs outline medical necessity, step therapy, and documentation requirements. Always refer to the most current version of the relevant CPB.

Does Aetna require step therapy for Xultophy?

Aetna's step therapy protocols, if applicable to Xultophy, are detailed within the relevant Clinical Policy Bulletins (CPBs). It is essential to consult the specific CPB to understand any prerequisite therapies or other utilization management requirements before submission.

What are common reasons for Xultophy PA denials by Aetna?

Common reasons for Xultophy prior authorization denials by Aetna include insufficient documentation of medical necessity, failure to meet step therapy requirements as outlined in the CPB, or situations where the requested use is considered off-label without adequate clinical support.

How do Aetna's PA turnaround times affect Xultophy requests?

Aetna's prior authorization turnaround times are governed by state regulations and NCQA standards. For Medicare Advantage and Medicaid plans, CMS-0057-F mandates 72-hour decisions for standard requests and 24-hour for expedited. Providers should verify the specific timeframes applicable to the patient's plan and state of residence.

Related coverage

Other xultophy prior authorization by payer

Other xultophy prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo